首页> 外文期刊>Journal of pharmaceutical investigation >Design and development of fluoxetine hydrochloride oro flash films to alleviate major depressive disorder
【24h】

Design and development of fluoxetine hydrochloride oro flash films to alleviate major depressive disorder

机译:盐酸氟西汀口服闪光膜减轻严重抑郁症的设计与开发

获取原文
获取原文并翻译 | 示例
           

摘要

The current research concerns the development of the formulation of fluoxetine HC1 (anti-depressant) oro flashes the new prospective by using solvent casting method. Oro flashes are quick dissolving oral films and the materials used were hydrophilic. Fluoxetine HC1 formulations were developed since oro flashes improves bioavail-ability to attain onset of action, along with the patient compliance. Fluoxetine HC1 is used to treat major depressive disorder, bulimia nervosa (an eating disorder), obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder. Polyvinyl alcohol (PVA) undergoes polymerization and forms oro flash film. Five different formulations were developed by using different polymeric concentrations of PVA. Polyvinyl pyrollidone K30 (PVP K30) used as super disintegrating agent and plasticizer, whereas menthol and mannitol were used as sweetener, flavoring agent respectively and water as a solvent system. In the study five formulations (Fl, F2, F3, F4, and F5) were evaluated for the properties such as thickness, folding endurance, drug content uniformity, surface pH, in vitro disintegration time, dissolution studies, % moisture loss, % moisture uptake, weight variation test, conductivity test. Results revealed that, F3 formulation can be considered as best, which has morphological features are homogenous and transparent with optimum thickness 0.23 ± 0.02 jam, folding endurance (>250 times number of folds on the same crease), drug content uniformity (Xmax at 225 nm) 97.60 ± 1.28, surface pH 6.654 ± 0.020, in vitro disintegration time 11 ± 1.20 s, in vitro dissolution studies 97.30 ± 0.75 %, % moisture loss 5.021 ± 0.052 %, % moisture uptake 3.634 ± 0.102 %, weight variation test 48.74 ± 1.0, conductivity test 61 muS which has maximum drag release (97.3 %) which facilitates maximum bioavailability.
机译:目前的研究涉及氟西汀HCl(抗抑郁药)的配方开发,采用溶剂浇铸法使其具有新的前景。 Oro闪光剂是快速溶解的口腔膜,使用的材料是亲水性的。氟西汀HC1制剂之所以被开发,是因为口服闪光改善了生物利用度,从而达到了起效作用以及患者的依从性。氟西汀HC1用于治疗重度抑郁症,神经性贪食症(进食障碍),强迫症,惊恐症和经前烦躁不安。聚乙烯醇(PVA)发生聚合反应并形成闪光膜。通过使用不同的聚合物浓度的PVA,开发了五种不同的配方。聚乙烯吡咯烷酮K30(PVP K30)用作超级崩解剂和增塑剂,而薄荷醇和甘露醇分别用作甜味剂,调味剂和水作为溶剂体系。在研究中,对五种配方(F1,F2,F3,F4和F5)的性能进行了评估,例如厚度,耐折性,药物含量均匀性,表面pH值,体外崩解时间,溶出度研究,%水分损失,%水分摄取,体重变化测试,电导率测试。结果表明,F3制剂可被认为是最好的,其形态特征是均质且透明的,具有最佳厚度0.23±0.02卡纸,耐折性(> 250倍相同折痕的折叠次数),药物含量均匀性(Xmax为225) nm)97.60±1.28,表面pH值6.654±0.020,体外崩解时间11±1.20 s,体外溶出度研究97.30±0.75%,水分损失百分率5.021±0.052%,水分吸收百分率3.634±0.102%,重量变化试验48.74 ±1.0,电导率测试61μS,具有最大的阻力释放(97.3%),有助于最大的生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号